Promising combo aims to wipe out early breast cancer before surgery

NCT ID NCT06604858

Ongoing Disease control Sponsor: MedSIR Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can eliminate all signs of cancer in people with early-stage triple-negative breast cancer before they have surgery. About 31 participants with small tumors (1 to 2.5 cm) that haven't spread to lymph nodes will receive the combination. The main goal is to see how many have no cancer left at the time of surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Locations

Complejo Hospitalario Universitario A Coruña (CHUAC)

A Coruña, Spain
Complejo Hospitalario Universitario de Santiago (CHUS)

Santiago de Compostela, Spain
Hospital Arnau de Vilanova de Valencia

Valencia, Spain
Hospital Beata María Ana

Madrid, Spain
Hospital Cínico San Carlos

Madrid, Spain
Hospital Universitari Dexeus

Barcelona, Spain
Hospital Universitari Vall D'Hebron

Barcelona, Spain
Hospital Universitario Clínico San Cecilio de Granada

Granada, Spain
Hospital Universitario Virgen del Rocío

Seville, Spain
Hospital Universitario de Navarra

Pamplona, Spain
Institut Català d' Oncologia Girona (ICO)

Girona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.